Safety and Efficacy of Switching Anticoagulation to Aspirin Three Months after Successful Radiofrequency Catheter Ablation of Atrial Fibrillation
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: Although current guidelines recommend continuing the same antithromboticstrategy regardless of rhythm control after radiofrequency catheter ablation (RFCA) of atrial fibrillation (AF), anticoagulation has a risk of major bleeding. We evaluated the safety of switching warfarin to aspirin in patients with successful AF ablation. Materials and Methods: Among 721 patients who underwent RFCA of AF, 608 patients (age, 57.3±10.9 years; 77.0% male, 75.5% paroxysmal AF) who had no evidence of AF recurrence at 3 months post-RFCA were included. We comparedthe thromboembolic and hemorrhagic events in patients for whom warfarin was switched to aspirin (ASA group; n=296) and patients who were kept on warfarin therapy (W group; n=312). Results: There were no significant differences in CHA2DS2-VASc or HAS-BLED scores between the groups. In 30 patients in the ASA group and 37 patients in W group, AF recurred and warfarin was restarted or maintained during the 18.0±12.2 months of follow-up. There were no significant differencesin thromboembolic (0.3% vs. 1.0%, p=0.342) and major bleeding incidences(0.7% vs. 0.6%, p=0.958) between ASA and W groups during the follow-up period. In the 259 patients with a CHA2DS2-VASc score ≥2, there were no significant differences in thromboembolism (0.8% and 2.2%, p=0.380) or major bleeding incidences(0.8% and 1.4%, p=0.640) between ASA and W groups. Conclusion: Switching warfarin to aspirin 3 months after successful RFCA of AF could be as safe and efficacious as long-term anticoagulation even in patients with CHA2DS2-VASc score ≥2. However, strict rhythm monitoring cannot be overemphasized.
Abstract
Purpose: Although current guidelines recommend continuing the same antithromboticstrategy regardless of rhythm control after radiofrequency catheter ablation (RFCA) of atrial fibrillation (AF), anticoagulation has a risk of major bleeding. We evaluated the safety of switching warfarin to aspirin in patients with successful AF ablation. Materials and Methods: Among 721 patients who underwent RFCA of AF, 608 patients (age, 57.3±10.9 years; 77.0% male, 75.5% paroxysmal AF) who had no evidence of AF recurrence at 3 months post-RFCA were included. We comparedthe thromboembolic and hemorrhagic events in patients for whom warfarin was switched to aspirin (ASA group; n=296) and patients who were kept on warfarin therapy (W group; n=312). Results: There were no significant differences in CHA2DS2-VASc or HAS-BLED scores between the groups. In 30 patients in the ASA group and 37 patients in W group, AF recurred and warfarin was restarted or maintained during the 18.0±12.2 months of follow-up. There were no significant differencesin thromboembolic (0.3% vs. 1.0%, p=0.342) and major bleeding incidences(0.7% vs. 0.6%, p=0.958) between ASA and W groups during the follow-up period. In the 259 patients with a CHA2DS2-VASc score ≥2, there were no significant differences in thromboembolism (0.8% and 2.2%, p=0.380) or major bleeding incidences(0.8% and 1.4%, p=0.640) between ASA and W groups. Conclusion: Switching warfarin to aspirin 3 months after successful RFCA of AF could be as safe and efficacious as long-term anticoagulation even in patients with CHA2DS2-VASc score ≥2. However, strict rhythm monitoring cannot be overemphasized.
참고문헌 (34)
- Wyse DG, "A comparison of rate control and rhythm control in patients with atrial fibrillation", N Engl J Med, 347, pp.1825~1833 (2002)
- Van Gelder IC, "A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation", N Engl J Med, 347, pp.1834~1840 (2002)
- Gage BF, "Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation", JAMA, 285, pp.2864~2870 (2001)
- Lip GY, "Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation", Chest, 137, pp.263~272 (2010)
- European Heart Rhythm Association, "Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)", Eur Heart J, 31, pp.2369~2429 (2010)
- Lee BH, "The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1", J Cardiovasc Electrophysiol, 21, pp.501~507 (2010)
- Wazni OM, "Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial", JAMA, 293, pp.2634~2640 (2005)
- Jaïs P, "Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study", Circulation, 118, pp.2498~2505 (2008)
- Cosedis Nielsen J, "Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation", N Engl J Med, 367, pp.1587~1595 (2012)
- Calkins H, "2012 HRS", EHRA, Heart Rhythm, pp.2012, 9[DOI]
- Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
- Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)
- Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 365, pp.981~992 (2011)
- Pisters R, "A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey", Chest, 138, pp.1093~1100 (2010)
- Verma A, "Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial", Eur Heart J, 31, pp.1344~1356 (2010)
- Pak HN, "Comparison of voltage map-guided left atrial anterior wall ablation versus left lateral mitral isthmus ablation in patients with persistent atrial fibrillation", HEART RHYTHM, 8(2), pp.199~206 (2011), ELSEVIER SCIENCE INC
- European Heart Rhythm Association (EHRA), "HRS", EHRA, Heart Rhythm, pp.2007, 4[DOI]
- Kastrati A, "Bivalirudin versus unfractionated heparin during percutaneous coronary intervention", N Engl J Med, 359, pp.688~696 (2008)
- Hart RG, "Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation", Ann Intern Med, 146, pp.857~867 (2007)
- Friberg L, "Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study", Eur Heart J, 33, pp.1500~1510 (2012)
- Olesen JB, "Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study", Thromb Haemost, 106, pp.739~749 (2011)
- Sato H, "Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial", Stroke, 37, pp.447~451 (2006)
- Lip GY, "Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and", or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), 2010, pp.31, 1311~1318
- Spaulding C, "A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents", N Engl J Med, 356, pp.989~997 (2007)
- Oral H, "Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation", Circulation, 114, pp.759~765 (2006)
- Nademanee K, "Clinical outcomes of catheter substrate ablation for high-risk patients with atrial fibrillation", J Am Coll Cardiol, 51, pp.843~849 (2008)
- Cappato R, "Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation", Circulation, 111, pp.1100~1105 (2005)
- Yagishita A, "Incidence of late thromboembolic events after catheter ablation of atrial fibrillation", Circ J, 75, pp.2343~2349 (2011)
- Corrado A, "Efficacy, safety, and outcome of atrial fibrillation ablation in septuagenarians", J Cardiovasc Electrophysiol, 19, pp.807~811 (2008)
- Themistoclakis S, "The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation", J Am Coll Cardiol, 55, pp.735~743 (2010)
- Bunch TJ, "Warfarin is not needed in low-risk patients following atrial fibrillation ablation procedures", J Cardiovasc Electrophysiol, 20, pp.988~993 (2009)
- Saad EB, "Very low risk of thromboembolic events in patients undergoing successful catheter ablation of atrial fibrillation with a CHADS2 score ≤3: a long-term outcome study", Circ Arrhythm Electrophysiol, 4, pp.615~621 (2011)
- Joshi S, "Prevalence, predictors, and prognosis of atrial fibrillation early after pulmonary vein isolation: findings from 3 months of continuous automatic ECG loop recordings", J Cardiovasc Electrophysiol, 20, pp.1089~1094 (2009)
- Shim J, "Long duration of radiofrequency energy delivery is an independent predictor of clinical recurrence after catheter ablation of atrial fibrillation: Over 500 cases experience", INTERNATIONAL JOURNAL OF CARDIOLOGY, 167(6), pp.2667~2672 (2013), Elsevier BV